STK11 and non-small cell lung carcinoma: STK11 mutations are recorded in approximately 20–30% of NSCLC cases, with a higher prevalence in adenocarcinoma subtypes compared to squamous cell carcinomas, and they deactivate the LBK1 protein [156].